Skip to Content

Join the 'High Cholesterol - Familial Heterozygous' group to help and get support from people like you.

High Cholesterol - Familial Heterozygous News

Related terms: Familial Hypercholesterolemia, Heterozygous, Heterozygous Familial Hypercholesterolemia, Heterozygous FH, Hypercholesterolemia, Familial Heterozygous

Powerful New Cholesterol Med Won't Harm Memory, Easing Concerns

Posted 17 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 16, 2017 – Despite some early concerns, a new study suggests the powerful cholesterol drugs known as PCSK9 inhibitors may not cause memory problems or other mental symptoms. The drugs, which include evolocumab (Repatha) and alirocumab (Praluent), were approved in the United States in 2015. That came after trials showed they can dramatically slash LDL cholesterol (the "bad" kind), including in people with a genetic condition that often causes premature heart disease. But early findings also hinted at a potential side effect: cognitive problems such as memory lapses and confusion. The risk was small, though, and it was not clear whether the drugs were actually causing the problems. Enter the new study. It's the first to actually follow PCSK9 patients over time, looking for new memory problems or other cognitive issues, said lead researcher Dr. Robert Giugliano. The study ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Pravachol, Livalo, Mild Cognitive Impairment, Red Yeast Rice, High Cholesterol - Familial Homozygous, Repatha, Praluent, Lescol, Hyperlipoproteinemia, Lescol XL

Is the 'Anti-Statin' Trend Threatening Lives?

Posted 25 Jul 2017 by Drugs.com

MONDAY, July 24, 2017 – A wave of anti-science skepticism may put people with high cholesterol at risk if they're convinced to quit life-saving statin medications, heart experts warn. An "internet-driven cult" is attacking the safety and effectiveness of cholesterol-lowering statins, despite mounds of clinical trial data showing the drugs work and produce minimal side effects, said Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic. "Unfortunately, we're in an era now where, with the internet, people with fringe views like this can gain the upper hand," Nissen said. "They've been very aggressive promoting to the public the idea that these drugs that are responsible for saving millions of lives are somehow bad for you." Most side effects associated with statins are minor and can be addressed by adjusting the dose or switching to another type of statin, Nissen ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Hyperlipoproteinemia Type IIa (Elevated LDL), Lescol, Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Lescol XL

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent (alirocumab) Injection

Posted 1 May 2017 by Drugs.com

BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017 /PRNewswire/ – Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly (every four weeks), 300 mg dose of Praluent (alirocumab) Injection for the treatment of adults with high low-density lipoprotein (LDL) cholesterol. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL cholesterol. The effect of Praluent on cardiovascular (CV) morbidity and mortality has not been determined. "The FDA approval of once-monthly Praluent is encouraging news for patients with clinical ASCVD or ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

Many Heart Attack Patients Fail to Stick With Statins

Posted 19 Apr 2017 by Drugs.com

WEDNESDAY, April 19, 2017 – High doses of powerful statin drugs have been shown to avert future heart problems, including heart attack and stroke. Yet many heart attack patients stop taking these medicines as recommended, a new study reveals. Researchers examined data for heart attack patients who had a prescription for a "high-intensity" statin filled within 30 days of being discharged from the hospital. Two years later, only 42 percent were taking these medicines regularly, the study found. Thirteen percent switched to a low- or moderate-intensity statin, while 19 percent weren't taking a statin regularly. Close to 1 in 5 stopped taking any statin altogether, the researchers said. The lack of adherence to recommended high-intensity statin therapy is short-sighted, suggested study lead author Dr. Robert Rosenson. "The message is that the benefits of statins continue to accrue over ... Read more

Related support groups: Ischemic Stroke, High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Transient Ischemic Attack, Zocor, Lovastatin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Pravachol, Livalo, Prevention of Cardiovascular Disease, Red Yeast Rice, Ischemic Stroke - Prophylaxis, Cardiovascular Risk Reduction, Thromboembolic Stroke Prophylaxis

Conflicting Statin Guidelines Leave Millions in 'Gray Zone'

Posted 18 Apr 2017 by Drugs.com

TUESDAY, April 18, 2017 – Conflicting guidelines on statin use could leave about 9 million Americans unsure about treatment, a new study suggests. Researchers estimate that if all doctors followed the latest guidelines from the U.S. Preventive Services Task Force (USPSTF) for the cholesterol-lowering drugs, the number of Americans aged 40 to 75 on statin medications would rise by 16 percent. In absolute numbers, that would mean another 17 million statin users. If that sounds like a big jump, consider what would happen if all doctors followed the advice of the American College of Cardiology/American Heart Association: Statin use would climb by 24 percent – for an additional 26 million Americans on the drugs, the study authors estimated. The difference between the two sets of guidelines leaves 9 million Americans in a statin "gray zone." So, which guidelines are "right"? That's not ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Vytorin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Pravachol, Livalo, Red Yeast Rice, High Cholesterol - Familial Homozygous, Caduet, Simcor, Lescol, Hyperlipoproteinemia

Routine Checkup Should Assess Fitness, Too

Posted 4 Jan 2017 by Drugs.com

TUESDAY, Jan. 3, 2017 – Most people know they should have their height, weight, blood pressure and cholesterol checked regularly, but an exercise expert says cardiorespiratory fitness should also be part of a routine medical exam. Cardiorespiratory fitness is a measure of how much work your body can do during exercise. "This measurement is so important because it shows how the heart, lungs and muscles all work together, and it should be an element of assessment of heart disease risk along with factors like smoking history, diabetes, and [high blood pressure]," said Dr. Benjamin Levine. He is a professor of internal medicine at UT Southwestern Medical Center, and director of the Institute of Exercise and Environmental Medicine, which is run by UT Southwestern and Texas Health Resources. "Decades of tests have clearly demonstrated that the ability to do aerobic exercise is strongly ... Read more

Related support groups: High Blood Pressure, Obesity, Hypertension, Weight Loss, High Cholesterol, High Cholesterol - Familial Heterozygous, Prevention of Cardiovascular Disease, Cardiovascular Risk Reduction, Hypertensive Heart Disease

Migraine and Stroke Risk Linked Again

Posted 15 Nov 2016 by Drugs.com

TUESDAY, Nov. 15, 2016 – Women who experience migraines have more than double the risk of suffering a stroke, new research shows. The finding adds evidence to the suspected link between these two conditions. Although it's not yet clear why this connection may exist, study lead author Dr. Cecil Rambarat said it's important for health care providers to be aware of the link. "This is important since migraine is generally not considered a risk factor for cardiovascular disease," said Rambarat. He's a resident physician at the University of Florida Shands Hospital in Gainesville. "Maybe providers need to factor in migraine headaches as a potential risk factor for cardiovascular disease among women," he said. "This is not being done currently." Previous research has linked migraines – especially the form known as migraine with aura – to stroke. Migraine with aura is estimated to affect one ... Read more

Related support groups: Plan B, Migraine, Mirena, Nexplanon, Depo-Provera, Provera, NuvaRing, Sprintec, Implanon, Ortho Tri-Cyclen, Tri-Sprintec, Microgestin Fe 1/20, Yasmin, Plan B One-Step, Loestrin 24 Fe, Smoking, Ortho Evra, Heart Disease, TriNessa, High Cholesterol

Coming Soon: Lower Cholesterol From a Twice-a-Year Shot?

Posted 15 Nov 2016 by Drugs.com

TUESDAY, Nov. 15, 2016 – Instead of popping a pill every day, people might soon control "bad" LDL cholesterol by getting an injection at their doctor's office two or three times a year. Researchers testing a new injectable drug called Inclisiran found it cut LDL cholesterol by half or more. According to early clinical trial data, the effect could last for four to six months. Inclisiran produced "significant and durable reductions in LDL cholesterol, and thus could potentially impact cardiovascular events," said study presenter Dr. Kausik Ray, a professor of public health at Imperial College London in England. Such long-lasting effects could provide a major advance in preventing heart disease, heart attack and stroke, by helping reduce hardening of the arteries, the researchers said. The trial results were presented Tuesday at the American Heart Association annual meeting in New ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Repatha, Caduet, Lescol, Hyperlipoproteinemia, Mevacor

Parent-Child Screening Urged for Inherited Heart Condition

Posted 27 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 26, 2016 – Young children should be screened for a type of genetic heart disease that significantly increases their risk of a heart attack at a young age, a new British study suggests. The screening could also identify parents with familial hypercholesterolemia. The condition, which causes high cholesterol levels, is the main inherited cause of early heart disease, the study authors said. Without preventive medication, people with familial hypercholesterolemia have a 10-fold increased risk of heart attack before age 40, the study noted. Researchers tested more than 10,000 children in England and found that one in 270 had familial hypercholesterolemia. That rate is nearly double the previously reported one in 500, the researchers said. After a child with familial hypercholesterolemia was identified, their parents underwent screening. Overall, one in every 125 persons ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Prevention of Cardiovascular Disease, High Cholesterol - Familial Homozygous, Cardiovascular Risk Reduction, Diagnosis and Investigation

Are There Alternatives to Statins?

Posted 27 Sep 2016 by Drugs.com

TUESDAY, Sept. 27, 2016 – Statins are the go-to therapy for lowering "bad" LDL cholesterol, but other treatments also can effectively reduce risk of future heart problems, a new evidence review reports. These alternative therapies – including a heart-healthy diet, other cholesterol-lowering medications, and even intestinal bypass surgery – seem to confer the same level of heart health protection as statins when cholesterol levels decrease, according to the findings. Nonstatin therapies reduced the risk of heart problems by 25 percent for each 1 millimole per liter (mmol/L) decrease in LDL cholesterol levels. That's very similar to the 23 percent reduction per 1 mmol/L decrease seen with statins like atorvastatin (Lipitor) and simvastatin (Zocor), the researchers said. What's more, the benefits of these therapies stack up if more than one proves effective at lowering a person's ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Welchol, Cholestyramine, Zocor, Lovastatin, Zetia, Vytorin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Gastric Bypass Surgery, Questran, Pravachol, Livalo, Red Yeast Rice

FDA Approves Repatha (evolocumab) Pushtronex - First And Only Single Monthly Injection for a PCSK9 Inhibitor

Posted 1 Aug 2016 by Drugs.com

THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 mg of Repatha in a single dose. Repatha is a human monoclonal antibody that blocks a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9), which inhibits the body's natural system for eliminating "bad" cholesterol (low-density lipoprotein cholesterol or LDL-C) from the blood.1 Repatha is the first and only PCSK9 inhibitor to offer a monthly single-dose delivery option. Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge) "The Pushtronex system exemplifies Amgen's continued innovation and c ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Repatha, Evolocumab

Inherited Cholesterol Disorder Significantly Boosts Heart Risks

Posted 30 Jun 2016 by Drugs.com

THURSDAY, June 30, 2016 – People who inherit a genetic disorder that causes high levels of "bad" LDL cholesterol have an increased risk for heart disease and hardened arteries, a new study finds. The condition is called heterozygous familial hypercholesterolemia. It's believed to affect about 1.5 million people in the United States, the researchers said. The genes linked to this condition prevent the liver from removing LDL (low-density lipoprotein) cholesterol from the blood. This allows the bad cholesterol to build up. Doctors suspect this familial condition when LDL levels are above 190 milligrams per deciliter (mg/dL), the study authors explained. The researchers reviewed data from six groups of people involved in previous studies. Compared to people with average LDL cholesterol levels (less than 130 mg/dL), those with familial hypercholesterolemia had a five times higher risk for ... Read more

Related support groups: Heart Disease, High Cholesterol, High Cholesterol - Familial Heterozygous, Prevention of Cardiovascular Disease, Cardiovascular Risk Reduction

Genetic High-Cholesterol Condition More Common Than Thought

Posted 14 Mar 2016 by Drugs.com

MONDAY, March 14, 2016 – Twice as many people as previously thought are genetically predisposed to develop dangerously high cholesterol levels, new research suggests. Familial hypercholesterolemia, as this condition is called, significantly ups the risk for an early heart attack. The study found it affects about one in every 250 American men and women, rather than one in 500. The new numbers don't reflect a problem on the rise, however, said study author Dr. Sarah de Ferranti, an assistant professor of pediatrics at Harvard Medical School. Instead, the condition was previously "under-recognized," she explained. For those who have this potentially deadly condition, "it is extremely important to get early, consistent preventive care," de Ferranti said. "The key is for you and your clinician to understand and distinguish between mild to moderately high cholesterol that comes on in middle ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Zetia, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Ezetimibe, Hyperlipoproteinemia Type IIa (Elevated LDL), Lescol, Hyperlipoproteinemia

Statins May Reduce Heart Risks Linked to Sleep Apnea: Study

Posted 6 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – A new discovery about the way sleep apnea may raise the risk of heart disease also suggests that taking cholesterol-lowering statin drugs might reduce that risk, according to a new study. Sleep apnea is a common disorder that involves irregular breathing while asleep, with oxygen intake dropping frequently for brief periods. The condition can triple a person's risk of stroke, high blood pressure and other heart problems, said study author Dr. Sanja Jelic, an associate professor of medicine at Columbia University Medical Center in New York City. Statins such as Crestor (rosuvastatin) and Lipitor (atorvastatin) are already taken by millions of Americans to reduce their risk of heart disease. "If the beneficial effects of statins on blood vessel health in patients with obstructive sleep apnea is confirmed in larger clinical trials, obstructive sleep apnea may ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Sleep Apnea, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Cardiovascular Risk Reduction, Hyperlipoproteinemia Type IIa (Elevated LDL), Obstructive Sleep Apnea/Hypopnea Syndrome, Lescol

U.S. Task Force Backs Statins for Those 40 to 75 at Heightened Heart Risk

Posted 22 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Cholesterol-lowering statin drugs should be used to prevent a first heart attack or stroke in certain at-risk patients, according to a draft recommendation released Monday by the nation's leading experts in preventive medicine. The U.S. Preventive Services Task Force said statins can provide maximum preventive benefits for adults 40 to 75 years old who have an existing risk factor for heart disease and at least a 10 percent or greater risk of a heart attack or stroke sometime within the next 10 years. The independent panel added that people with a 10-year risk of heart attack and stroke between 7.5 percent and 10 percent might also benefit from statins, and should discuss the matter with their doctor. "Cardiovascular disease is a leading cause of death, and people with no signs or symptoms or past history of cardiovascular disease can still be at risk," said ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, High Cholesterol - Familial Heterozygous, Hypertriglyceridemia, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Hyperlipoproteinemia Type IIa (Elevated LDL), Lescol, Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Lescol XL

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol

Related Drug Support Groups

Lipitor, simvastatin, Crestor, atorvastatin, pravastatin, Zocor, lovastatin, Zetia, Vytorin, view more... rosuvastatin, Pravachol, Repatha, Praluent, ezetimibe, Lescol, Lescol XL, Mevacor, Advicor, alirocumab, Altoprev, fluvastatin, evolocumab, simvastatin / sitagliptin, lovastatin / niacin, Altocor, Juvisync, ezetimibe / simvastatin, Repatha Pushtronex